KR-20260062484-A - Composition for preventing, improving or treating diabetes comprising isosakuranetin

Abstract

The present invention relates to a composition for the prevention, improvement, or treatment of diabetes or complications of diabetes, comprising isosakuranetin as an active ingredient. A composition containing isosakuranetin as an active ingredient according to the present invention has the effect of inhibiting an increase in blood sugar, activating liver and/or kidney function, and inhibiting damage to liver and/or kidney tissue, and can be utilized for the prevention, improvement, or treatment of diabetes or complications of diabetes.

Inventors

• 김소희
• 김형수
• 최현겸

Assignees

• 아주대학교산학협력단

Dates

Publication Date

20260507

Application Date

20241029

Claims (13)

1. A pharmaceutical composition for the prevention or treatment of diabetes or complications of diabetes, comprising isosakuranetin or a pharmaceutically acceptable salt thereof as an active ingredient.
2. In paragraph 1, A pharmaceutical composition in which the above-mentioned diabetes is type 1 diabetes or type 2 diabetes.
3. In paragraph 1, A pharmaceutical composition wherein the above-mentioned diabetes complication is one or more selected from the group consisting of diabetic nephropathy, diabetic retinopathy, diabetic cataract, diabetic neuropathy, diabetic ulcer, diabetic heart disease, diabetic osteoporosis, and diabetic arteriosclerosis.
4. In paragraph 1, The above composition is a pharmaceutical composition that inhibits an increase in blood sugar.
5. In paragraph 1, The above composition is a pharmaceutical composition that inhibits damage to liver tissue or kidney tissue.
6. In paragraph 1, The above composition is a pharmaceutical composition that activates liver function or kidney function.
7. A quasi-drug composition for the prevention or improvement of diabetes or complications of diabetes, comprising isosakuranetin or a pharmaceutically acceptable salt thereof as an active ingredient.
8. A food composition for the prevention or improvement of diabetes or complications of diabetes, comprising isosakuranetin as an active ingredient.
9. In paragraph 8, The above composition is a food composition that inhibits an increase in blood sugar.
10. In paragraph 8, A food composition that inhibits damage to liver tissue or kidney tissue.
11. In paragraph 8, The above composition is a food composition that activates liver function or kidney function.
12. A health functional food comprising a food composition according to any one of paragraphs 8 to 11.
13. A feed composition for the prevention or improvement of diabetes or complications of diabetes, comprising isosakuranetin as an active ingredient.

Description

Composition for preventing, improving or treating diabetes comprising isosakuranetin The present invention relates to a composition for the prevention, improvement, or treatment of diabetes or complications of diabetes, comprising isosakuranetin or a pharmaceutically acceptable salt thereof as an active ingredient. Recently, the incidence of chronic metabolic diseases such as diabetes is rising due to changes in dietary habits and reduced physical activity. According to the Korea National Health and Nutrition Examination Survey, the prevalence of diabetes among adults aged 30 and older in Korea was reported to be 16.7% as of 2020, while it stood at 30.1% for the elderly aged 65 and older. Diabetes is a metabolic disease characterized by hyperglycemia and hyperdiabetes; it is primarily characterized by reduced insulin secretion due to the destruction or dysfunction of pancreatic β-cells responsible for insulin secretion, as well as rejection of insulin receptors in tissues caused by genetic factors or obesity, which prevents blood glucose from being transported to tissues and leads to its excretion through urine. Once diabetes is induced, the secretion of insulin and glucagon is disrupted, causing abnormalities in metabolic regulatory functions—not only regarding carbohydrates but also protein and lipid metabolism—leading to various metabolic diseases. Furthermore, if diabetic symptoms persist for a long time, thickening of the epithelial membranes of capillaries occurs, posing a problem by causing numerous complications in the circulatory system and other areas. Diabetes can be classified based on the presence or absence of insulin production into Type 1 diabetes, an insulin-dependent condition in which no insulin is produced at all, and Type 2 diabetes, an insulin-independent condition in which insulin is produced but relatively insufficient. More than 90% of all diabetes patients fall under Type 2 diabetes, which is caused by reduced insulin secretion from pancreatic beta cells or increased insulin resistance in peripheral tissues (Artasensi et al., 2020). If insulin secretion is delayed or insufficient, glucose utilization in tissues such as the liver, muscle, and fat decreases, and glucose production in the liver fails to decrease, leading to insulin resistance and abnormalities in glucose and lipid metabolism. Causes include genetic factors as well as high-calorie and high-fat diets resulting from the Westernization of dietary habits, lack of exercise, stress, obesity, and medication use. The most important goal in diabetes treatment is to control blood glucose levels as close to normal as possible. Treatment methods include drug therapy, dietary therapy, and exercise therapy, but it is primarily treated by taking hypoglycemic agents in conjunction with dietary control and exercise. Against this background, the inventors have completed the present invention by confirming that isosakuranetin has the effect of inhibiting the increase in blood sugar, activating liver and/or kidney functions, and inhibiting damage to liver and/or kidney tissues, and thus can be utilized for the prevention, improvement, or treatment of diabetes and its complications. Figure 1 shows the mean values of the initial and final body weights, and the relative ratios (%) of liver and kidney to final body weight, of CON, ISN, STZ, and STZ-ISN rats in a diabetes-induced animal model. Data are expressed as mean ± standard deviation, ** p < 0.01, *** p < 0.001. Figure 2 shows the changes in blood glucose, GOP, and GPT levels in CON, ISN, STZ, and STZ-ISN rats in an animal model of diabetes induction. Data are expressed as mean ± standard deviation, * p < 0.05, ** p < 0.01, *** p < 0.001. Figure 3 shows the changes in urea nitrogen, serum creatinine (S cr ), creatinine clearance (CL CR ), and albumin levels in CON, ISN, STZ, and STZ-ISN rats in an animal model of diabetes induction. Data are expressed as mean ± standard deviation, * p < 0.05, ** p < 0.01. Figure 4 shows the results of observing morphological changes in liver and kidney tissues of CON, ISN, STZ, and STZ-ISN mice in a diabetes-induced animal model. An asterisk (*) indicates large-scale apoptosis and tissue damage. Figure 5 shows the blood tofacitinib concentration-times in CON, ISN, STZ, and STZ-ISN rats after intravenous (Figure 5A) and oral (Figure 5B) administration of tofacitinib in an animal model of diabetes induction. Figure 5A shows the mean arterial plasma concentration-time curves after intravenous infusion of tofacitinib at a dose of 10 mg/kg over 1 minute in the CON (n = 8), ISN (n = 7), STZ (n = 6), and STZ-ISN (n = 9) groups. Figure 5B shows the mean arterial plasma concentration-time curves after oral administration of tofacitinib at a dose of 20 mg/kg in the CON (n = 7), ISN (n = 7), STZ (n = 6), and STZ-ISN (n = 7) groups. Figure 6 shows the mean values of V max , K m , and CL int obtained by measuring the rate at which tofacitinib disappeared from liver